Blair William & Co. IL Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Blair William & Co. IL raised its position in shares of Pfizer Inc. (NYSE:PFE) by 85.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,953,310 shares of the biopharmaceutical company’s stock after buying an additional 902,376 shares during the quarter. Blair William & Co. IL’s holdings in Pfizer were worth $54,654,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Gilbert & Cook Inc. increased its holdings in shares of Pfizer by 3.8% during the fourth quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 945 shares in the last quarter. Gryphon Financial Partners LLC increased its holdings in Pfizer by 43.7% in the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock worth $861,000 after buying an additional 8,194 shares in the last quarter. Quest Partners LLC bought a new stake in Pfizer in the 4th quarter worth about $186,000. Aigen Investment Management LP bought a new stake in Pfizer in the 4th quarter worth about $867,000. Finally, InterOcean Capital Group LLC increased its holdings in Pfizer by 5.3% in the 4th quarter. InterOcean Capital Group LLC now owns 25,864 shares of the biopharmaceutical company’s stock worth $745,000 after buying an additional 1,291 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.3 %

PFE stock opened at $29.75 on Thursday. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.11. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock has a market cap of $168.58 billion, a P/E ratio of -495.75, a PEG ratio of 1.02 and a beta of 0.68. The business’s 50-day moving average price is $29.33 and its 200-day moving average price is $28.19.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the previous year, the firm earned $0.67 EPS. The business’s quarterly revenue was up 2.1% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were issued a $0.42 dividend. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.65%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analysts Set New Price Targets

Several research firms recently commented on PFE. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. UBS Group lifted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.